The effects of E-cadherin and bcl-2 on prognosis in patients with breast cancer

Bratislava Medical Journal

Volumn 111, Issue 9, 2010, Pages 493-497

  Kavgaci, H ^a   Yildiz, B ^a   Fidan, E ^a   Reis, A ^a   Ozdemir, F ^a   Cobanoglu, U ^a   Can, G ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Bcl 2; Breast cancer; E cadherin

Indexed keywords

CADHERIN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ARTICLE; BREAST TUMOR; CHEMISTRY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG CARCINOMA; LYMPH NODE METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PROGNOSIS;

BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77957970090     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Mori I, Yang Q, Kakudo K. Predictive and prognostic markers for invasive breast cancer. Pathol Int 2002; 52 (3): 186-194.
2. Wood WC, Muss HB et al. Malignant Tumors of Breast. 1415-1488. In: DeVita VT, Hellman S, Rosenberg SA (Eds). Principles and Practice of Oncology. 7th ed. Philadelphia; Lippincott Williams and WilMns, 2005.
3. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003; 5 (6): 217-222.
4. Arun B, Kilic G, Yen C et al. Correlation Bcl-2 and p53 Expression in Primary Breast Tumors and Corresponding Metastatic Lymph Nodes. Cancer 2003; 98 (12): 2554-2559.
5. Bozzetti C, Nizzoli R, Naldi N et al. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma. Cancer 1999; 87 (4): 224-230.
6. Park SH, Kim H, Song BJ. Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen- and progesterone-receptor dependent and associated with poor prognostic factors. Pathol Oncol Res 2002; 8 (1): 26-30.
7. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000; 89 (1): 51-62.
8. Wu J, Shao ZM, Shen ZZ et al. Significance of apoptosis and apo-ptotic-related proteins, Bcl-2 and Bax in primary breast Cancer. The Breast Journal 2000; 6 (1): 44-52.
9. Wright C, Nicholson S, Angus B et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65 (1): 118-121.
10. Pedrini JL, Pedrini M, Savaris RF, Machado L, Grudzinski M, Zettler CG. Reassessing tumor markers in local recurrences of breast cancer: a new insight. Med Sci Monit 2004; 10 (12): 462-467.
11. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 2004; 198 (1): 83-90.
12. Fritz P, Cabrera CM, Dippon J et al. C-erbB2 and topoisomerase II alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res 2005; 7 (3): 374-384.
13. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005; 46 (6): 685-693.
14. Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res 2000; 60 (2): 298-304.
15. Sidoni A, Cavaliere A, Bellezza G et al. Coexpression of HER-2/neu and p53 in breast cancer identifies a subset with an aggressive bio-pathological profile. Tumori 2006; 92 (5): 412-415.
16. Margulis A, Zhang W, Alt-Holland A et al. Loss of intercellular adhesion activates a transition from low- to high-grade human squamous cell carcinoma. Int J Cancer 2006; 118 (4): 821-831.
17. Goyal A, Martin TA, Mansel RE, Jiang WG. Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome. World J Surg Oncol 2008, 6 (56): 1-6.
18. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjänen K. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J Pathol 1994; 174 (2): 101-109.
19. Parker C, Rampaul RS, Pinder SE et al. E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 2001; 85 (12): 1958-1963.
20. Shao Z, Jiang M, Wu J et al. Inhibition of spontaneous apoptosis in human breast cancer. Chin Med Sci J 1996; 11 (4): 200-203.
21. Yang Q, Sakurai T, Jing X et al. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol Int 1999; 49 (9): 775-780.
22. Eissa S, Labib R, Khalifa A, Swelam N, Khalil F, El-Shenawy AM. Regulators of apoptosis inhuman breast cancer. Clin Biochem 1999; 32 (5): 321-326.
23. Al-Moundhri M, Nirmala V, Al-Mawaly K et al. Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res 2003; 9 (4): 226-231.
24. Grace MC, Mark JW, Paul DPP. Meta-analysis confirms BCL2 is an independent prognostic markerin breast cancer. BMC Cancer 2008; 8 (153): 1-10.